Novartis AG $NVS Shares Acquired by Simplicity Wealth LLC

Simplicity Wealth LLC increased its holdings in shares of Novartis AG (NYSE:NVS) by 140.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,586 shares of the company’s stock after acquiring an additional 5,016 shares during the period. Simplicity Wealth LLC’s holdings in Novartis were worth $1,039,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. WPG Advisers LLC acquired a new position in shares of Novartis during the 1st quarter worth approximately $25,000. Tsfg LLC raised its position in Novartis by 366.0% during the first quarter. Tsfg LLC now owns 233 shares of the company’s stock worth $26,000 after acquiring an additional 183 shares during the period. Barrett & Company Inc. purchased a new position in Novartis during the second quarter valued at $31,000. MCF Advisors LLC lifted its holdings in Novartis by 66.0% during the second quarter. MCF Advisors LLC now owns 264 shares of the company’s stock valued at $32,000 after purchasing an additional 105 shares in the last quarter. Finally, Highline Wealth Partners LLC grew its position in shares of Novartis by 82.4% in the second quarter. Highline Wealth Partners LLC now owns 290 shares of the company’s stock valued at $35,000 after purchasing an additional 131 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

NYSE NVS opened at $132.35 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The stock’s fifty day moving average is $123.90 and its two-hundred day moving average is $117.38. The firm has a market capitalization of $279.58 billion, a P/E ratio of 19.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.64. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $133.55.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, July 17th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The business had revenue of $14.05 billion for the quarter, compared to analyst estimates of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.97 EPS. On average, research analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Wall Street Zen lowered Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Saturday, September 27th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 target price (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $120.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.